Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Stem Cell Transplantation With CD34-Selected PBSC in Treatment Resistant Systemic Sclerosis
NCT03630211Phase 2Recruiting
- Sponsor
- Paul Szabolcs
- Start
- Jul 2018
- Primary completion
- Aug 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous cd34-selected peripheral blood stem cells in systemic sclerosis (SSc), sponsored by Paul Szabolcs. Started Jul 2018; status: recruiting.
02
Drugs
autologous cd34-selected peripheral blood stem cells
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT03630211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630211.